Joint Statement: health organisations define EHDS’ opt out required for life saving research
9 Jun 2023
On the 6th of June, EORTC joined together with 31 other health stakeholders to share views on specific recommendations for a potential opt-out mechanism in the future EHDS.
These organisations and initiatives have joined forces because they all share the view that health data are precious and renewable resources that can power decision-making for clinical care, deliver life-saving innovations, and strengthen health systems in the 21st century.
Discussions in the EU policy-making process now include proposals for an opt-out mechanism for citizens to withdraw their data from secondary use purposes (that is, from research, regulatory purposes and evidence-based policy making). The original European Commission proposal did not include this mechanism.
The group of stakeholders support the approach taken in the Commission’s original legislative proposal from May 2022 as it strikes a sensible balance between the protection of personal data while enabling the use of data for research and innovation to create tangible benefits for patients and citizens. The stakeholders raised concerns about the real risk that data bias will form part of the EHDS from its inception and thus undermine its principal value for secondary use research purposes if an opt-out or opt-in mechanism is approved, and call for an impact assessment that will inform the implementation of this policy option.
If the proposals for opt-out are approved in the final EHDS legislation, the group make six recommendations. They believe the opt-out mechanism should:
- be applicable across all Health Data Access Bodies in EU Member States, limiting the scope of national derogation and ensuring that the technical specifications are aligned.
- consider the impact on health and care professionals and other data holders.
- be capable of implementation across the EU, without limiting lawful and ethical data sharing for secondary purposes.
- be routinely monitored as part of a regularly updated HealthData@EU data governance framework.
- have a limited, but well-defined, consistent and transparent scope.
- have necessary investment, infrastructure and budget to ensure sufficient transparency so that citizens are well informed of the opt-out.
Finally, the current debate on enabling the secondary use of health data in Europe highlights the need to achieve stakeholder alignment where possible on the implementation journey ahead for the EHDS. It also speaks to the need for implementation decisions to be highly informed by those with experience and responsibilities for on-the-ground implementation. This reiterates a need for strong, balanced and inclusive stakeholder representation within the governance model of the EHDS such as its Board of Directors.
Read the full statement here.
Related News
EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma
11 Dec 2024
Minister F. Vandenbroucke visits EORTC Headquarters to strengthen collaborative efforts in clinical cancer research
21 Nov 2024
IMMUcan has completed patient enrolment
12 Nov 2024
EORTC SPRINT clinical cancer study receives support from Rising Tide Foundation to reduce the burden for patients
5 Nov 2024
Pink October at EORTC: Over 60 years of impactful breast cancer research
29 Oct 2024
Spotlight on ENA 2024 News
25 Oct 2024
Do regulations and policies undermine the social value of independent academic research?
25 Oct 2024
EORTC Quality of Life Group’s participation to ISOQOL 2024
10 Oct 2024
New Insights into Glioblastoma Treatment for Older Adults Patients
8 Oct 2024
TOPGEAR trial results show no significant benefit of preoperative chemoradiotherapy on long term survival
24 Sep 2024